- Home
- APXT vs LRMR Comparison
APXT vs LRMR Comparison
Compare APXT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APXT | LRMR |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.8M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | APXT | LRMR |
|---|---|---|
| Price | $9.94 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 41.4K | ★ 2.2M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,368.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $1.61 |
| 52 Week High | $10.00 | $6.42 |
Technical Indicators
Market Signals| Indicator | APXT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 49.04 |
| Support Level | N/A | $3.09 |
| Resistance Level | $10.00 | $5.37 |
| Average True Range (ATR) | 0.01 | 0.36 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 14.28 | 23.55 |
Price Performance
Historical ComparisonAbout APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.